FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as high-risk subgroup of acute T-lymphoblastic leukemia (T-ALL) with a high rate of FLT3-mutations in adults. To unravel the underlying pathomechanisms and the clinical course we assessed molecular alterations and clin...

Full description

Saved in:
Bibliographic Details
Main Authors: Neumann, Martin (Author) , Hofmann, Wolf-Karsten (Author)
Format: Article (Journal)
Language:English
Published: 2013
In: PLOS ONE
Year: 2013, Volume: 8, Issue: 1
ISSN:1932-6203
DOI:10.1371/journal.pone.0053190
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1371/journal.pone.0053190
Verlag, kostenfrei, Volltext: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053190
Get full text
Author Notes:Martin Neumann, Ebru Coskun, Lars Fransecky, Liliana H. Mochmann, Isabelle Bartram, Nasrin Farhadi Sartangi, Sandra Heesch, Nicola Gökbuget, Stefan Schwartz, Christian Brandts, Cornelia Schlee, Rainer Haas, Ulrich Dührsen, Martin Griesshammer, Hartmut Döhner, Gerhard Ehninger, Thomas Burmeister, Olga Blau, Eckhard Thiel, Dieter Hoelzer, Wolf-Karsten Hofmann, Claudia D. Baldus

MARC

LEADER 00000caa a2200000 c 4500
001 1576867919
003 DE-627
005 20220814174831.0
007 cr uuu---uuuuu
008 180626s2013 xx |||||o 00| ||eng c
024 7 |a 10.1371/journal.pone.0053190  |2 doi 
035 |a (DE-627)1576867919 
035 |a (DE-576)506867919 
035 |a (DE-599)BSZ506867919 
035 |a (OCoLC)1341012921 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Neumann, Martin  |d 1982-  |e VerfasserIn  |0 (DE-588)1017465991  |0 (DE-627)690346581  |0 (DE-576)353772909  |4 aut 
245 1 0 |a FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors  |c Martin Neumann, Ebru Coskun, Lars Fransecky, Liliana H. Mochmann, Isabelle Bartram, Nasrin Farhadi Sartangi, Sandra Heesch, Nicola Gökbuget, Stefan Schwartz, Christian Brandts, Cornelia Schlee, Rainer Haas, Ulrich Dührsen, Martin Griesshammer, Hartmut Döhner, Gerhard Ehninger, Thomas Burmeister, Olga Blau, Eckhard Thiel, Dieter Hoelzer, Wolf-Karsten Hofmann, Claudia D. Baldus 
264 1 |c 2013 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published: January 24, 2013 
500 |a Gesehen am 26.06.2018 
520 |a Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) has been identified as high-risk subgroup of acute T-lymphoblastic leukemia (T-ALL) with a high rate of FLT3-mutations in adults. To unravel the underlying pathomechanisms and the clinical course we assessed molecular alterations and clinical characteristics in a large cohort of ETP-ALL (n = 68) in comparison to non-ETP T-ALL adult patients. Interestingly, we found a high rate of FLT3-mutations in ETP-ALL samples (n = 24, 35%). Furthermore, FLT3 mutated ETP-ALL was characterized by a specific immunophenotype (CD2+/CD5-/CD13+/CD33-), a distinct gene expression pattern (aberrant expression of IGFBP7, WT1, GATA3) and mutational status (absence of NOTCH1 mutations and a low frequency, 21%, of clonal TCR rearrangements). The observed low GATA3 expression and high WT1 expression in combination with lack of NOTCH1 mutations and a low rate of TCR rearrangements point to a leukemic transformation at the pluripotent prothymocyte stage in FLT3 mutated ETP-ALL. The clinical outcome in ETP-ALL patients was poor, but encouraging in those patients with allogeneic stem cell transplantation (3-year OS: 74%). To further explore the efficacy of targeted therapies, we demonstrate that T-ALL cell lines transfected with FLT3 expression constructs were particularly sensitive to tyrosine kinase inhibitors. In conclusion, FLT3 mutated ETP-ALL defines a molecular distinct stem cell like leukemic subtype. These data warrant clinical studies with the implementation of FLT3 inhibitors in addition to early allogeneic stem cell transplantation for this high risk subgroup. 
650 4 |a Acute myeloid leukemia 
650 4 |a Apoptosis 
650 4 |a Chemotherapy 
650 4 |a Gene expression 
650 4 |a Leukemias 
650 4 |a Pediatrics 
650 4 |a T cells 
650 4 |a Tyrosine kinase inhibitors 
700 1 |a Hofmann, Wolf-Karsten  |d 1967-  |e VerfasserIn  |0 (DE-588)114154635  |0 (DE-627)691208751  |0 (DE-576)351568336  |4 aut 
773 0 8 |i Enthalten in  |t PLOS ONE  |d San Francisco, California, US : PLOS, 2006  |g 8(2013,1) Artikel-Nummer e53190, 10 Seiten  |h Online-Ressource  |w (DE-627)523574592  |w (DE-600)2267670-3  |w (DE-576)281331979  |x 1932-6203  |7 nnas  |a FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors 
773 1 8 |g volume:8  |g year:2013  |g number:1  |a FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors 
856 4 0 |u http://dx.doi.org/10.1371/journal.pone.0053190  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053190  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180626 
993 |a Article 
994 |a 2013 
998 |g 114154635  |a Hofmann, Wolf-Karsten  |m 114154635:Hofmann, Wolf-Karsten  |d 60000  |d 61200  |e 60000PH114154635  |e 61200PH114154635  |k 0/60000/  |k 1/60000/61200/  |p 21 
999 |a KXP-PPN1576867919  |e 3013830115 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title":"FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors","title_sort":"FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors"}],"person":[{"role":"aut","family":"Neumann","display":"Neumann, Martin","given":"Martin"},{"role":"aut","family":"Hofmann","display":"Hofmann, Wolf-Karsten","given":"Wolf-Karsten"}],"recId":"1576867919","origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"2013"}],"name":{"displayForm":["Martin Neumann, Ebru Coskun, Lars Fransecky, Liliana H. Mochmann, Isabelle Bartram, Nasrin Farhadi Sartangi, Sandra Heesch, Nicola Gökbuget, Stefan Schwartz, Christian Brandts, Cornelia Schlee, Rainer Haas, Ulrich Dührsen, Martin Griesshammer, Hartmut Döhner, Gerhard Ehninger, Thomas Burmeister, Olga Blau, Eckhard Thiel, Dieter Hoelzer, Wolf-Karsten Hofmann, Claudia D. Baldus"]},"relHost":[{"title":[{"title":"PLOS ONE","title_sort":"PLOS ONE"}],"name":{"displayForm":["Public Library of Science"]},"origin":[{"dateIssuedDisp":"2006-","publisher":"PLOS ; PLoS","publisherPlace":"San Francisco, California, US ; Lawrence, Kan.","dateIssuedKey":"2006"}],"corporate":[{"display":"Public Library of Science","role":"isb"}],"note":["Schreibweise des Titels bis 2012: PLoS ONE","Gesehen am 20.03.19"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2267670-3"],"issn":["1932-6203"],"eki":["523574592"]},"part":{"issue":"1","year":"2013","text":"8(2013,1) Artikel-Nummer e53190, 10 Seiten","volume":"8"},"language":["eng"],"disp":"FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsPLOS ONE","recId":"523574592","pubHistory":["1.2006 -"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"note":["Published: January 24, 2013","Gesehen am 26.06.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1371/journal.pone.0053190"],"eki":["1576867919"]}} 
SRT |a NEUMANNMARFLT3MUTATI2013